Table 5

Factors associated with achievement of CR in patients treated with curative intent using VEPEMB, ABVD, and CLVPP (157)

FactorNo. of patientsParameterP
Age 157 Comparison of age (60-69 y vs 70-79 y vs > 80 y) .32 
Sex 157 Male vs female .85 
Stage 157 1 vs 2 vs 3 vs 4 .15 
B symptoms 157 Present vs absent .89 
Histologic type 152 MC vs NS vs LRCHL vs unclassified .27 
No. of nodal sites 117 1-2 vs 3-4 vs > 4 .55 
Serum LDH 129 Normal vs abnormal .33 
Lymphocyte count 154 < 1 vs 1-2 vs > 2 × 109/L .40 
Hemoglobin 156 6-7.9 vs 8-9.9 vs 10-11.9 vs > 12 g/dL .04 
ADL 144 Maximum score 6 vs < 6 .001 
Comorbidity score (modified ACE-27) 155 Frail vs nonfrail CR, .01 
   OS, .001 
IDL 143 Score 0-2 vs 3-5 vs 6 vs 7-8 .01 
ECOG 145 0-1 vs 2-3 .02 
Bulk disease 145 Yes vs no .23 
Hasenclever Index 106 Low vs intermediate vs high .06 
Serum albumin 148 Normal vs abnormal .02 
EBV antigen Reed-Sternberg cells(available on VEPEMB patients only) 94 Positive vs negative .71 
FactorNo. of patientsParameterP
Age 157 Comparison of age (60-69 y vs 70-79 y vs > 80 y) .32 
Sex 157 Male vs female .85 
Stage 157 1 vs 2 vs 3 vs 4 .15 
B symptoms 157 Present vs absent .89 
Histologic type 152 MC vs NS vs LRCHL vs unclassified .27 
No. of nodal sites 117 1-2 vs 3-4 vs > 4 .55 
Serum LDH 129 Normal vs abnormal .33 
Lymphocyte count 154 < 1 vs 1-2 vs > 2 × 109/L .40 
Hemoglobin 156 6-7.9 vs 8-9.9 vs 10-11.9 vs > 12 g/dL .04 
ADL 144 Maximum score 6 vs < 6 .001 
Comorbidity score (modified ACE-27) 155 Frail vs nonfrail CR, .01 
   OS, .001 
IDL 143 Score 0-2 vs 3-5 vs 6 vs 7-8 .01 
ECOG 145 0-1 vs 2-3 .02 
Bulk disease 145 Yes vs no .23 
Hasenclever Index 106 Low vs intermediate vs high .06 
Serum albumin 148 Normal vs abnormal .02 
EBV antigen Reed-Sternberg cells(available on VEPEMB patients only) 94 Positive vs negative .71 

MC indicates mixed cellularity; NS, nodular sclerosis; LRCHL, lymphocyte-rich classic HL; and LDH, lactate dehydrogenase.

or Create an Account

Close Modal
Close Modal